Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Assets (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Assets over the past 15 years, most recently at $239.3 million for Q2 2025.

  • For Q2 2025, Assets fell 5.76% year-over-year to $239.3 million; the TTM value through May 2025 reached $239.3 million, down 5.76%, while the annual FY2025 figure was $239.3 million, 5.76% down from the prior year.
  • Assets for Q2 2025 was $239.3 million at Lifecore Biomedical, Inc. \De\, up from $237.7 million in the prior quarter.
  • Over five years, Assets peaked at $506.9 million in Q1 2021 and troughed at $236.7 million in Q1 2023.
  • A 5-year average of $304.3 million and a median of $254.7 million in 2024 define the central range for Assets.
  • Biggest five-year swings in Assets: skyrocketed 71.0% in 2021 and later tumbled 45.27% in 2022.
  • Year by year, Assets stood at $421.3 million in 2021, then plummeted by 34.5% to $276.0 million in 2022, then dropped by 10.93% to $245.8 million in 2023, then grew by 3.89% to $255.4 million in 2024, then fell by 6.28% to $239.3 million in 2025.
  • Business Quant data shows Assets for LFCR at $239.3 million in Q2 2025, $237.7 million in Q1 2025, and $255.4 million in Q4 2024.